tetano
Editor, Senior Moderator
Nat Med
. 2020 Jul 10.
doi: 10.1038/s41591-020-0998-x. Online ahead of print.
Rapid Isolation and Profiling of a Diverse Panel of Human Monoclonal Antibodies Targeting the SARS-CoV-2 Spike Protein
Seth J Zost[SUP] 1 [/SUP], Pavlo Gilchuk[SUP] 1 [/SUP], Rita E Chen[SUP] 2 3 [/SUP], James Brett Case[SUP] 3 [/SUP], Joseph X Reidy[SUP] 1 [/SUP], Andrew Trivette[SUP] 1 [/SUP], Rachel S Nargi[SUP] 1 [/SUP], Rachel E Sutton[SUP] 1 [/SUP], Naveenchandra Suryadevara[SUP] 1 [/SUP], Elaine C Chen[SUP] 4 [/SUP], Elad Binshtein[SUP] 1 [/SUP], Swathi Shrihari[SUP] 3 [/SUP], Mario Ostrowski[SUP] 5 [/SUP], Helen Y Chu[SUP] 6 [/SUP], Jonathan E Didier[SUP] 7 [/SUP], Keith W MacRenaris[SUP] 7 [/SUP], Taylor Jones[SUP] 1 [/SUP], Samuel Day[SUP] 1 [/SUP], Luke Myers[SUP] 1 [/SUP], F Eun-Hyung Lee[SUP] 8 [/SUP], Doan C Nguyen[SUP] 8 [/SUP], Ignacio Sanz[SUP] 8 [/SUP], David R Martinez[SUP] 9 [/SUP], Paul W Rothlauf[SUP] 10 11 [/SUP], Louis-Marie Bloyet[SUP] 11 [/SUP], Sean P J Whelan[SUP] 10 11 [/SUP], Ralph S Baric[SUP] 9 [/SUP], Larissa B Thackray[SUP] 3 [/SUP], Michael S Diamond[SUP] 2 3 11 12 [/SUP], Robert H Carnahan[SUP] 13 14 [/SUP], James E Crowe Jr[SUP] 15 16 17 [/SUP]
Affiliations
Abstract
Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date[SUP]1,2[/SUP]. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes on the basis of their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of advanced antibody discovery platforms.
. 2020 Jul 10.
doi: 10.1038/s41591-020-0998-x. Online ahead of print.
Rapid Isolation and Profiling of a Diverse Panel of Human Monoclonal Antibodies Targeting the SARS-CoV-2 Spike Protein
Seth J Zost[SUP] 1 [/SUP], Pavlo Gilchuk[SUP] 1 [/SUP], Rita E Chen[SUP] 2 3 [/SUP], James Brett Case[SUP] 3 [/SUP], Joseph X Reidy[SUP] 1 [/SUP], Andrew Trivette[SUP] 1 [/SUP], Rachel S Nargi[SUP] 1 [/SUP], Rachel E Sutton[SUP] 1 [/SUP], Naveenchandra Suryadevara[SUP] 1 [/SUP], Elaine C Chen[SUP] 4 [/SUP], Elad Binshtein[SUP] 1 [/SUP], Swathi Shrihari[SUP] 3 [/SUP], Mario Ostrowski[SUP] 5 [/SUP], Helen Y Chu[SUP] 6 [/SUP], Jonathan E Didier[SUP] 7 [/SUP], Keith W MacRenaris[SUP] 7 [/SUP], Taylor Jones[SUP] 1 [/SUP], Samuel Day[SUP] 1 [/SUP], Luke Myers[SUP] 1 [/SUP], F Eun-Hyung Lee[SUP] 8 [/SUP], Doan C Nguyen[SUP] 8 [/SUP], Ignacio Sanz[SUP] 8 [/SUP], David R Martinez[SUP] 9 [/SUP], Paul W Rothlauf[SUP] 10 11 [/SUP], Louis-Marie Bloyet[SUP] 11 [/SUP], Sean P J Whelan[SUP] 10 11 [/SUP], Ralph S Baric[SUP] 9 [/SUP], Larissa B Thackray[SUP] 3 [/SUP], Michael S Diamond[SUP] 2 3 11 12 [/SUP], Robert H Carnahan[SUP] 13 14 [/SUP], James E Crowe Jr[SUP] 15 16 17 [/SUP]
Affiliations
- PMID: 32651581
- DOI: 10.1038/s41591-020-0998-x
Abstract
Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date[SUP]1,2[/SUP]. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes on the basis of their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of advanced antibody discovery platforms.